CD274 (PD-L1, B7-H1) Monoclonal Antibody (MIH5), APC, eBioscience | Invitrogen 17-5982-82 product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

CD274 (PD-L1, B7-H1) Monoclonal Antibody (MIH5), APC, eBioscience

catalog :

17-5982-82

quantity :

100 µg

price :

US 369

clonality :

monoclonal

host :

rat

conjugate :

APC

clone name :

MIH5

reactivity :

mouse

application :

flow cytometry

more info or order :

Invitrogen product webpage

citations: 24

Published Application/Species/Sample/Dilution	Reference
flow cytometry; mouse; 1:100; loading ...; fig s6a, s6b	Shi L, Wang J, Ding N, Zhang Y, Zhu Y, Dong S, et al. Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy. Nat Commun. 2019;10:5421 pubmed publisher
	Li W, Zhao C, Li W, Gong Y, Ma K, Lu Y, et al. BRAF D594A mutation defines a unique biological and immuno-modulatory subgroup associated with functional CD8+ T cell infiltration in colorectal cancer. J Transl Med. 2023;21:737 pubmed publisher
	Xu S, Cai J, Cheng H, Wang W. Sustained release of therapeutic gene by injectable hydrogel for hepatocellular carcinoma. Int J Pharm X. 2023;6:100195 pubmed publisher
	Blangero F, Robert M, Andraud T, Dumontet C, Vidal H, Eljaafari A. Contribution of Mesenchymal Stem Cells from Obese Adipose Tissue to PD-L1 Over-Expression and Breast Cancer Progression through Pathogenic Th17 Cell Activation. Cancers (Basel). 2023;15: pubmed publisher
	Zhang G, Lan B, Zhang X, Lin M, Liu Y, Chen J, et al. AR-A014418 regulates intronic polyadenylation and transcription of PD-L1 through inhibiting CDK12 and CDK13 in tumor cells. J Immunother Cancer. 2023;11: pubmed publisher
	Ebelt N, Manuel E. 5-Azacytidine-Mediated Modulation of the Immune Microenvironment in Murine Acute Myeloid Leukemia. Cancers (Basel). 2022;15: pubmed publisher
	Mao M, Chen Y, Yang J, Cheng Y, Xu L, Ji F, et al. Modification of PLAC8 by UFM1 affects tumorous proliferation and immune response by impacting PD-L1 levels in triple-negative breast cancer. J Immunother Cancer. 2022;10: pubmed publisher
	Shen S, Li Y, Jin M, Fan D, Pan R, Lin A, et al. CD4+ CTLs Act as a Key Effector Population for Allograft Rejection of MSCs in a Donor MHC-II Dependent Manner in Injured Liver. Aging Dis. 2022;13:1919-1938 pubmed publisher
	Zhang X, Halberstam A, Zhu W, Leitner B, Thakral D, Bosenberg M, et al. Isotope tracing reveals distinct substrate preference in murine melanoma subtypes with differing anti-tumor immunity. Cancer Metab. 2022;10:21 pubmed publisher
	Wang X, Chen Y, Lan B, Wang Y, Lin W, Jiang X, et al. Heterogeneity of tyrosine-based melanin anabolism regulates pulmonary and cerebral organotropic colonization microenvironment of melanoma cells. Theranostics. 2022;12:2063-2079 pubmed publisher
	Hagemans I, Wierstra P, Steuten K, Molkenboer Kuenen J, van Dalen D, ter Beest M, et al. Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents. J Nanobiotechnology. 2022;20:64 pubmed publisher
	Yang K, Choi C, Cho H, Ahn W, Kim S, Shin S, et al. Antigen-Capturing Mesoporous Silica Nanoparticles Enhance the Radiation-Induced Abscopal Effect in Murine Hepatocellular Carcinoma Hepa1-6 Models. Pharmaceutics. 2021;13: pubmed publisher
	Yang Z, Xu G, Wang B, Liu Y, Zhang L, Jing T, et al. USP12 downregulation orchestrates a protumourigenic microenvironment and enhances lung tumour resistance to PD-1 blockade. Nat Commun. 2021;12:4852 pubmed publisher
	Ebelt N, Zamloot V, Zuniga E, Passi K, Sobocinski L, Young C, et al. Collagenase-Expressing Salmonella Targets Major Collagens in Pancreatic Cancer Leading to Reductions in Immunosuppressive Subsets and Tumor Growth. Cancers (Basel). 2021;13: pubmed publisher
	Eissa I, Mukoyama N, Abdelmoneim M, Naoe Y, Matsumura S, Bustos Villalobos I, et al. Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8+ PD-1- tumor-infiltrating T cells in PD-L1-enriched tumor microenvironment. Int J Cancer. 2021;149:214-227 pubmed publisher
	Ferrere G, Tidjani Alou M, Liu P, Goubet A, Fidelle M, Kepp O, et al. Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. JCI Insight. 2021;6: pubmed publisher
	Yoo G, Ahn W, Kim S, Kang W, Choi C, Park H. Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study. Clin Mol Hepatol. 2021;27:144-156 pubmed publisher
	Gao H, Wu Y, Shi J, Zhang X, Liu T, Hu B, et al. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy. J Immunother Cancer. 2020;8: pubmed publisher
	Wu B, Chiang H, Sun X, Yuan B, Mitra P, Hu Y, et al. Genetic ablation of adipocyte PD-L1 reduces tumor growth but accentuates obesity-associated inflammation. J Immunother Cancer. 2020;8: pubmed publisher
	Neuwelt A, Kimball A, Johnson A, Arnold B, Bullock B, Kaspar R, et al. Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms. J Immunother Cancer. 2020;8: pubmed publisher
	Zhang J, Yamada O, Kida S, Murase S, Hattori T, Oshima Y, et al. Downregulation of PD-L1 via amide analogues of brefelamide: Alternatives to antibody-based cancer immunotherapy. Exp Ther Med. 2020;19:3150-3158 pubmed publisher
	Zhou Z, Chen H, Xie R, Wang H, Li S, Xu Q, et al. Epigenetically modulated FOXM1 suppresses dendritic cell maturation in pancreatic cancer and colon cancer. Mol Oncol. 2019;13:873-893 pubmed publisher
	Zamarin D, Ricca J, Sadekova S, Oseledchyk A, Yu Y, Blumenschein W, et al. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J Clin Invest. 2018;128:1413-1428 pubmed publisher
	Hirata Y, Furuhashi K, Ishii H, Li H, Pinho S, Ding L, et al. CD150high Bone Marrow Tregs Maintain Hematopoietic Stem Cell Quiescence and Immune Privilege via Adenosine. Cell Stem Cell. 2018;22:445-453.e5 pubmed publisher

product information

Product Type :

Antibody

Product Name :

CD274 (PD-L1, B7-H1) Monoclonal Antibody (MIH5), APC, eBioscience

Catalog # :

17-5982-82

Quantity :

100 µg

Price :

US 369

Clonality :

Monoclonal

Purity :

Affinity chromatography

Host :

Rat

Reactivity :

Mouse

Applications :

Flow Cytometry: 0.25 µg/test

Species :

Mouse

Clone :

MIH5

Isotype :

IgG2a, lambda

Storage :

4° C, store in dark, DO NOT FREEZE!

Description :

Programmed death receptor ligand 1 (PD-L1, also called B7-H1) is a recently described B7 family member. To date, one specific receptor has been identified that can be ligated by PD-L1. This receptor, programmed death receptor 1 (PD-1), has been shown to negatively regulate T-cell receptor (TCR) signaling. Upon ligating its receptor, PD-L1 has been reported to decrease TCR-mediated proliferation and cytokine production. PD-L1 expression was found to be abundant on many murine and human cancers and could be further up-regulated upon IFN-gamma stimulation. Thus, PD-L1 might play an important role in tumor immune evasion.

Format :

Liquid

Applications w/Dilutions :

Flow Cytometry: 0.25 µg/test

Aliases :

A530045L16Rik; B7 homolog 1; B7-H; B7h1; B7-H1; Cd274; CD274 antigen; CD274 molecule; PDCD1 ligand 1; Pdcd1l1; Pdcd1lg1; Pdl1; PD-L1; pdl-1; Programmed cell death 1 ligand 1; programmed death ligand 1; RGD1566211; sCD274; soluble CD274; soluble PD L1; sPD L1

more info or order :

Invitrogen product webpage